Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Item 7.01 – Regulation FD: On 30 Jul 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished an 8-K announcing it has received a Notice of Intent to Grant for European patent application “Preparation of Pre-liposomal Annamycin Lyophilizate.”
The disclosure, provided via attached Exhibit 99.1, indicates the patent is expected to cover the Company’s Annamycin formulation in Europe once formally issued. No financial statements, earnings data or other operational metrics are included. The information is expressly furnished, not filed, and therefore will not be incorporated into other Exchange Act or Securities Act reports unless later referenced. Exhibit 104 supplies the Inline XBRL cover page.
Moleculin Biotech (MBRX) has announced a significant public offering totaling $5.9 million in gross proceeds, with potential for an additional $17.8 million if all warrants are exercised. The offering, which closed on June 23, 2025, includes:
- 9,972,026 shares of common stock
- 6,107,974 pre-funded warrants at $0.001 exercise price
- 48,240,000 Series E warrants at $0.37 initial exercise price
Notable aspects include insider participation, with CEO Walter Klemp and CFO Jonathan Foster purchasing 1,027,026 shares and 3,081,078 warrants. Roth Capital Partners served as placement agent, receiving a 7% fee. The proceeds will fund clinical development of Annamycin and two other drug portfolios, preclinical studies, and working capital.
The offering includes significant stockholder approval requirements and anti-dilution provisions, with warrant exercise prices subject to potential downward adjustments (floor price $0.12). The company has agreed to a 60-day restriction on new share issuances following stockholder approvals.
Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech (MBRX), reported multiple securities transactions on June 20-23, 2025:
- Acquired 2,711 shares from RSUs and had 661 shares withheld for taxes on June 20
- Acquired 4,328 shares from RSUs and had 1,054 shares withheld for taxes on June 22
- Purchased 270,270 common shares at $0.37 per share in a public offering on June 23
- Acquired Series E warrants to purchase 810,810 shares at $0.37/share, exercisable upon stockholder approval with 5-year expiration
Following these transactions, Foster directly owns 287,587 common shares and 1,038,320 derivative securities. The RSUs were granted in 2022 (10,846 units) and 2023 (17,313 units), vesting in four annual installments. This significant insider purchase demonstrates management's confidence in the company's prospects.